156 related articles for article (PubMed ID: 10235483)
21. A rat experimental model for the design of vaccines against tumor associated antigens Tn and Sialyl-Tn.
Hallouin F; Goupille C; Rocher J; Le Pendu J
Glycoconj J; 1999 Nov; 16(11):681-4. PubMed ID: 11003551
[TBL] [Abstract][Full Text] [Related]
22. Anti-Tn human monoclonal antibodies generated following active immunization with partially desialylated ovine submaxillary mucin.
O'Boyle KP; Wright K
Hum Antibodies Hybridomas; 1994; 5(1-2):25-31. PubMed ID: 7532023
[TBL] [Abstract][Full Text] [Related]
23. Improving the antigenicity of sTn antigen by modification of its sialic acid residue for development of glycoconjugate cancer vaccines.
Wu J; Guo Z
Bioconjug Chem; 2006; 17(6):1537-44. PubMed ID: 17105234
[TBL] [Abstract][Full Text] [Related]
24. A cancer vaccine based on fluorine-modified sialyl-Tn induces robust immune responses in a murine model.
Song C; Zheng XJ; Liu CC; Zhou Y; Ye XS
Oncotarget; 2017 Jul; 8(29):47330-47343. PubMed ID: 28537884
[TBL] [Abstract][Full Text] [Related]
25. Evidence of a cellular immune response against sialyl-Tn in breast and ovarian cancer patients after high-dose chemotherapy, stem cell rescue, and immunization with Theratope STn-KLH cancer vaccine.
Sandmaier BM; Oparin DV; Holmberg LA; Reddish MA; MacLean GD; Longenecker BM
J Immunother; 1999 Jan; 22(1):54-66. PubMed ID: 9924700
[TBL] [Abstract][Full Text] [Related]
26. Immunization of breast cancer patients using a synthetic sialyl-Tn glycoconjugate plus Detox adjuvant.
MacLean GD; Reddish M; Koganty RR; Wong T; Gandhi S; Smolenski M; Samuel J; Nabholtz JM; Longenecker BM
Cancer Immunol Immunother; 1993; 36(4):215-22. PubMed ID: 8439984
[TBL] [Abstract][Full Text] [Related]
27. Synthesis of sialyl Lewis(a) (sLe (a), CA19-9) and construction of an immunogenic sLe(a) vaccine.
Ragupathi G; Damani P; Srivastava G; Srivastava O; Sucheck SJ; Ichikawa Y; Livingston PO
Cancer Immunol Immunother; 2009 Sep; 58(9):1397-405. PubMed ID: 19190907
[TBL] [Abstract][Full Text] [Related]
28. The role of cancer vaccines following autologous stem cell rescue in breast and ovarian cancer patients: experience with the STn-KLH vaccine (Theratope).
Holmberg LA; Oparin DV; Gooley T; Sandmaier BM
Clin Breast Cancer; 2003 Feb; 3 Suppl 4():S144-51. PubMed ID: 12620152
[TBL] [Abstract][Full Text] [Related]
29. Immunization of high-risk breast cancer patients with clustered sTn-KLH conjugate plus the immunologic adjuvant QS-21.
Gilewski TA; Ragupathi G; Dickler M; Powell S; Bhuta S; Panageas K; Koganty RR; Chin-Eng J; Hudis C; Norton L; Houghton AN; Livingston PO
Clin Cancer Res; 2007 May; 13(10):2977-85. PubMed ID: 17504999
[TBL] [Abstract][Full Text] [Related]
30. Glycosylations versus conformational preferences of cancer associated mucin core.
Schuman J; Qiu D; Koganty RR; Longenecker BM; Campbell AP
Glycoconj J; 2000 Dec; 17(12):835-48. PubMed ID: 11511808
[TBL] [Abstract][Full Text] [Related]
31. Synthesis and immunological properties of N-modified GM3 antigens as therapeutic cancer vaccines.
Pan Y; Chefalo P; Nagy N; Harding C; Guo Z
J Med Chem; 2005 Feb; 48(3):875-83. PubMed ID: 15689172
[TBL] [Abstract][Full Text] [Related]
32. An O-acetylated sialyl-Tn is involved in ovarian cancer-associated antigenicity.
Toba S; Tenno M; Kurosaka A
Biochem Biophys Res Commun; 2000 May; 271(2):281-6. PubMed ID: 10799288
[TBL] [Abstract][Full Text] [Related]
33. Synthesis and immunological evaluation of MUC1 glycopeptide conjugates bearing N-acetyl modified STn derivatives as anticancer vaccines.
Xiao A; Zheng XJ; Song C; Gui Y; Huo CX; Ye XS
Org Biomol Chem; 2016 Jul; 14(30):7226-37. PubMed ID: 27380866
[TBL] [Abstract][Full Text] [Related]
34. Monoclonal antibodies recognising sialyl-Tn: production and application to immunochemistry.
Devine PL; Birrell GW; Quin RJ; Shield PW
Dis Markers; 1995 Aug; 12(3):175-86. PubMed ID: 8590544
[TBL] [Abstract][Full Text] [Related]
35. Specificity analysis of murine monoclonal antibodies reactive with Tn, sialylated Tn, T, and monosialylated (2-->6) T antigens.
O'Boyle KP; Markowitz AL; Khorshidi M; Lalezari P; Longenecker BM; Lloyd KO; Welt S; Wright KE
Hybridoma; 1996 Dec; 15(6):401-8. PubMed ID: 8985750
[TBL] [Abstract][Full Text] [Related]
36. Thomsen-Friedenreich (TF) antigen as a target for prostate cancer vaccine: clinical trial results with TF cluster (c)-KLH plus QS21 conjugate vaccine in patients with biochemically relapsed prostate cancer.
Slovin SF; Ragupathi G; Musselli C; Fernandez C; Diani M; Verbel D; Danishefsky S; Livingston P; Scher HI
Cancer Immunol Immunother; 2005 Jul; 54(7):694-702. PubMed ID: 15726361
[TBL] [Abstract][Full Text] [Related]
37. Keyhole limpet hemocyanin conjugate vaccines against cancer: the Memorial Sloan Kettering experience.
Musselli C; Livingston PO; Ragupathi G
J Cancer Res Clin Oncol; 2001 Oct; 127 Suppl 2():R20-6. PubMed ID: 11768620
[TBL] [Abstract][Full Text] [Related]
38. Mucins bearing the cancer-associated sialosyl-Tn antigen mediate inhibition of natural killer cell cytotoxicity.
Ogata S; Maimonis PJ; Itzkowitz SH
Cancer Res; 1992 Sep; 52(17):4741-6. PubMed ID: 1511439
[TBL] [Abstract][Full Text] [Related]
39. Fluorine-modified sialyl-Tn-CRM197 vaccine elicits a robust immune response.
Song C; Zheng XJ; Guo H; Cao Y; Zhang F; Li Q; Ye XS; Zhou Y
Glycoconj J; 2019 Oct; 36(5):399-408. PubMed ID: 31267246
[TBL] [Abstract][Full Text] [Related]
40. Interactions of mucins with the Tn or Sialyl Tn cancer antigens including MUC1 are due to GalNAc-GalNAc interactions.
Haugstad KE; Hadjialirezaei S; Stokke BT; Brewer CF; Gerken TA; Burchell J; Picco G; Sletmoen M
Glycobiology; 2016 Dec; 26(12):1338-1350. PubMed ID: 27282157
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
